Accepts Medicare Nurse Practitioner in Chicago, Illinois.
Mrs. Habiba Seidu-fuseini is a Chicago, Illinois based nurse practitioner with 9 years of experience in . She completed her graduation in 2015. She accepts the Medicare-approved amount. Patients will not be billed for any more than the Medicare deductible and coinsurance. Her current practice location is 1629 N Natchez Ave, Chicago. Patients can reach her at 630-926-4225. Mrs. Habiba Seidu-fuseini is NP and her NPI number (Unique professional ID assigned by NPPES) is 1992037469. Mrs. Habiba Seidu-fuseini has completed additional training beyond basic nursing education and provides primary health care services in accordance with state nurse practice laws or statutes. NPs are trained to assess patient needs, order and interpret diagnostic and laboratory tests, diagnose disease, formulate and prescribe medications and treatment plans.
Complete Profile:
Mrs. Habiba Seidu-fuseini speciality, credentials, practice address, contact phone number and fax are as below.
Patients can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
PAC ID:
0446582449
Enrollment ID:
I20191024000233
NPI Number:
1992037469
NPI Enumeration Date:
08 Feb, 2010
NPI Last Update On:
12 May, 2023
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
Mrs. Habiba Seidu-fuseini 722 N Emroy Ave, Elmhurst, Illinois
Zip:
60126-1710
Phone Number:
773-622-4313
Fax Number:
773-290-2401
Patients can reach Mrs. Habiba Seidu-fuseini at 1629 N Natchez Ave, Chicago, Illinois or can call to book an appointment on 630-926-4225.
Comments/ Reviews:
Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 September, 2024.